Merus NV

Genmab A/S has completed its acquisition of Merus N.V. for $97.00 per share, leading to the delisting of Merus's common shares from Nasdaq.

Genmab A/S has completed its acquisition of Merus N.V. for approximately $6.9 billion, with 94.2% of shares tendered and significant board and executive leadership changes.

Merus N.V. shareholders overwhelmingly approved all proposals related to the Genmab A/S acquisition, including the $97.00 per share cash offer and director appointments.

Genmab A/S announced its intent to acquire Merus N.V. for $97.00 per share in an all-cash transaction, valued at approximately $8.0 billion, to expand its late-stage oncology pipeline.

Merus N.V. has entered into an underwriting agreement for a public offering of 5,263,158 common shares, with an option for additional shares, aiming to raise approximately $281.7 million in net proceeds to advance its clinical pipeline and fund operations into 2028.

Merus N.V. announced positive interim clinical data from its ongoing Phase 2 trial of the bispecific antibody petosemtamab in combination with pembrolizumab, showing high response rates and promising survival outcomes.

Merus N.V. reports Q3 2025 results, highlighting the pending Genmab acquisition offer, increased R&D spend on key oncology candidates, and a significant net loss, while maintaining a strong cash position into 2028.

Merus N.V. reports increased net losses driven by accelerated R&D for its oncology pipeline, while significantly bolstering its cash reserves to fund operations into 2028.

Merus N.V. reports a net loss of $96.5 million for Q1 2025, alongside increased revenue driven by commercial material sales and collaboration agreements.

Merus N.V., a clinical-stage oncology company, released its third quarter 2024 financial results, highlighting increased operating expenses and a net loss, alongside progress in clinical trials and collaborations.

Merus N.V. reports a net loss of $50 million for the second quarter of 2024, alongside significant advancements in clinical programs and a strong cash position.

Merus N.V., a clinical-stage oncology company, reported a net loss of $34.5 million for the first quarter of 2024, while highlighting progress in its clinical programs and a new collaboration with Gilead.

Merus N.V. files an amendment to its annual report on Form 10-K to include its Insider Trading Compliance Policy, which was inadvertently omitted from the original filing.

Merus N.V. details its financial performance for 2024 and provides an update on its clinical programs, including zenocutuzumab, petosemtamab, and MCLA-129.

Merus N.V., a clinical-stage oncology company, released its 2023 annual report, highlighting progress in its multispecific antibody programs and providing a financial overview.

Genmab A/S has finalized its acquisition of Merus N.V., converting all remaining minority shares into cash and delisting the company.

Genmab A/S, through its subsidiary, increased its beneficial ownership in Merus N.V. to over 72.8 million common shares following recent acquisitions as part of a tender offer.

Genmab A/S, through its subsidiary, has increased its beneficial ownership in Merus N.V. to over 94% following a tender offer and subsequent share acquisitions.

Genmab A/S, through its subsidiary, increased its beneficial ownership in Merus N.V. by acquiring additional common shares at $97.00 per share following a tender offer.

Merus N.V.'s Chief Financial Officer, Gregory D. Perry, disposed of all his share options on December 12, 2025, as part of Genmab's tender offer to acquire the company for $97.00 per share.

Merus N.V. director Anand Mehra disposed of all share options following Genmab's tender offer at $97.00 per share.

Genmab A/S, through its subsidiary, has launched a tender offer to acquire all outstanding common shares of Merus N.V. for $97.00 per share in cash, with Merus's Board unanimously recommending the offer.

Merus N.V. announced its agreement to be acquired by Genmab for approximately $8 billion in cash, or $97 per common share, representing a significant premium.

Merus N.V. announced an agreement to be acquired by Genmab A/S for approximately $8 billion in cash, or $97 per common share.

Genmab A/S announced its intent to acquire Merus N.V. for $97.00 per share in an all-cash transaction valued at approximately $8.0 billion, aiming to expand its late-stage oncology pipeline.

Merus N.V. announces its 2025 Annual General Meeting of Shareholders to be held on May 21, 2025, featuring proposals including the adoption of annual accounts, auditor appointment, director re-appointments, and executive compensation approval.

Merus N.V. files a proxy supplement to update the biographical information of two directors, Sven (Bill) Ante Lundberg and Mark Iwicki, ahead of its Annual General Meeting on May 7, 2024.

Genmab A/S and its subsidiary have successfully completed the tender offer and subsequent merger to acquire all outstanding shares of Merus N.V., leading to its delisting from Nasdaq.

Genmab A/S has successfully acquired a 94.8% stake in Merus N.V. through a tender offer priced at $97.00 per common share, moving towards full control and delisting.

Paradigm BioCapital Advisors LP and its affiliates have disclosed a 6.2% beneficial ownership stake in Merus N.V. common shares as of September 30, 2025.

RTW Investments, LP and Roderick Wong have reported a 2.7% beneficial ownership stake in Merus N.V. common shares as of September 30, 2025.

Wellington Management Group LLP and its affiliates have disclosed a 0.61% beneficial ownership stake in Merus N.V. common stock.

FMR LLC and Abigail P. Johnson have filed an amendment to their Schedule 13G, reporting a reduced beneficial ownership of 3.7% in Merus N.V. common stock.

Commodore Capital LP and Commodore Capital Master LP have disclosed a 4.7% beneficial ownership stake in Merus N.V., totaling 3,525,000 common shares.

Wellington Management Group LLP, along with its holding companies, reports beneficial ownership of 5.0% of Merus N.V.'s common stock as of June 30, 2025.